Trials / Conditions / EGFR Positive Non-small Cell Lung Cancer

EGFR Positive Non-small Cell Lung Cancer

21 registered clinical trials studyying EGFR Positive Non-small Cell Lung Cancer — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With NCT07298148	Peking University Cancer Hospital & Institute	Phase 2
Recruiting	Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification NCT07322783	Qingdao Central Hospital	Phase 2
Unknown	SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cance NCT06208033	Fujian Cancer Hospital	EARLY_Phase 1
Recruiting	Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935	Massachusetts General Hospital	N/A
Not Yet Recruiting	Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation NCT05962021	Peking University People's Hospital	Phase 2
Unknown	A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant No NCT05338619	Sung Yong Lee	Phase 2
Active Not Recruiting	Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study NCT05089916	AIO-Studien-gGmbH	Phase 2
Recruiting	Osimertinib for Advanced EGFR-positive NSCLC Patients NCT05037331	National University Hospital, Singapore	—
Unknown	A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant N NCT04643847	First People's Hospital of Hangzhou	Phase 2
Completed	Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis NCT07239102	Beijing Tiantan Hospital	—
Active Not Recruiting	Phase 2 Study of Dacomitinib in NSCLC NCT04027647	National Cancer Centre, Singapore	Phase 2
Active Not Recruiting	A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients NCT04001777	Ascentage Pharma Group Inc.	Phase 1
Completed	Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC NCT04105153	Thoraxklinik-Heidelberg gGmbH	—
Unknown	Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Pa NCT03382795	Korea University Guro Hospital	Phase 2
Completed	First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors NCT02729298	Sumitomo Pharma America, Inc.	Phase 1
Unknown	A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) NCT03126799	National Cancer Center, Korea	Phase 2
Unknown	A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations Aft NCT02788058	First People's Hospital of Hangzhou	Phase 2
Unknown	Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma NCT02125240	Betta Pharmaceuticals Co., Ltd.	Phase 3
Unknown	Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanc NCT02194556	Betta Pharmaceuticals Co., Ltd.	Phase 4
Unknown	Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Aden NCT02103257	Betta Pharmaceuticals Co., Ltd.	Phase 4
Unknown	Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma NCT01665417	Betta Pharmaceuticals Co., Ltd.	Phase 4